Citius Pharmaceuticals, Inc.
$0.87
▲
1.32%
2026-04-21 06:17:02
citiuspharma.com
NCM: CTXR
Explore Citius Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$19.56 M
Current Price
$0.87
52W High / Low
$2.48 / $0.63
Stock P/E
—
Book Value
$3.57
Dividend Yield
—
ROCE
-44.79%
ROE
-47.85%
Face Value
—
EPS
$-2.46
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
23
Beta
1.38
Debt / Equity
1.96
Current Ratio
0.99
Quick Ratio
0.13
Forward P/E
0.29
Price / Sales
4.57
Enterprise Value
$25.63 M
EV / EBITDA
-0.7
EV / Revenue
6.5
Rating
None
Target Price
$6
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Sol-Gel Technologies Ltd. | $70 | — | $228.83 M | — | -31.74% | -23.72% | $97.97 / $4.11 | $8.19 |
| 2. | MediciNova, Inc. | $1.47 | — | $71.37 M | — | -31.77% | -25.5% | $1.96 / $1.17 | $0.84 |
| 3. | AIM ImmunoTech Inc. | $0.49 | — | $3.99 M | — | 2638.91% | 251.38% | $19.74 / $0.51 | $-3.19 |
| 4. | Evaxion A/S | $4.49 | — | $37.11 M | — | -38.23% | -1% | $12.15 / $1.25 | $2.04 |
| 5. | ADC Therapeutics SA | $4.25 | — | $543.75 M | — | -42.38% | 73.43% | $4.98 / $1.13 | $-1.48 |
| 6. | Acumen Pharmaceuticals, Inc. | $2.84 | — | $203.64 M | — | -133.4% | -96.2% | $3.6 / $0.85 | $1.16 |
| 7. | Atara Biotherapeutics, Inc. | $4.99 | 1.29 | $42.24 M | — | 674.99% | -48.15% | $19.14 / $3.92 | $-5.26 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 3.94 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -9.02 M | -8.44 M | -8.79 M | -11.26 M | -10.04 M | — |
| Net Profit | -8.22 M | -7.96 M | -8.79 M | -10.92 M | -9.77 M | — |
| EPS in Rs | -0.37 | -0.36 | -0.39 | -0.49 | -0.44 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -38.53 M | -42 M | -36.73 M | -33.32 M |
| Net Profit | -37.43 M | -39.14 M | -32.54 M | -33.64 M |
| EPS in Rs | -1.67 | -1.75 | -1.45 | -1.5 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 130.94 M | 116.65 M | 103.61 M | 114 M |
| Total Liabilities | 53.41 M | 42.55 M | 12.18 M | 10.57 M |
| Equity | 67.55 M | 70.08 M | 90.83 M | 102.83 M |
| Current Assets | 27.93 M | 14.22 M | 34.37 M | 44.56 M |
| Current Liabilities | 44.91 M | 35.81 M | 5.78 M | 4.53 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -26.55 M | -28.2 M | -29.06 M | -28.36 M |
| Investing CF | -5.75 M | -5 M | 0 M | 0 M |
| Financing CF | 33.3 M | 9.97 M | 13.83 M | 0 M |
| Free CF | -26.55 M | -28.2 M | -29.06 M | -28.36 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -20.27% | 3.26% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-11-26 | 1:0.04 |